Thursday, 2 September 2010

Neptune "Very Undervalued" In Analyst Update

Neptune Technologies & Bioressources
Basic Shares: 40.2 million
Fully diluted: 43.1 million


Catalyst Equity Research analyst, Robin Cornwell has reiterated his Buy and emphasized "Very Undervalued", based on positive news from Neptune regarding pre-clinical test results for CaPre™ an investigational drug candidate for cholesterol management.

CaPre™ had a positive effect on C-reactive protein (CRP) levels, which is a biomarker of Cardiovascular (CVD) risk and is associated with obesity and diabetes.

The American Heart Association has recognized CRP levels in blood could be one more way to assess CVD risk.

Of note is Mr. Cornwell’s feelings on an expected IND (Investigational New Drug) filing and the positive impact on valuation that should accompany this initiative.

Click here to read his update and why he has set a one-year $5 target price.